Category: INO.com Contributors

If The Bitcoin ETF Is Approved, Should You Buy It?

Posted on by Matt Thalman

Matt Thalman - INO.com Contributor - ETFs


On March 11th, the Securities and Exchange Commission will release its ruling on whether or not a Bitcoin ETF will be approved. Back in 2013 the Winklevoss twins, you may remember them from the story on how Facebook Inc. (NASDAQ:FB) was started, filed for their Bitcoin Trust ETF to be approved. Others have been submitted since then, but that ETF will be the first to be approved or denied by the SEC.

Some experts believe the Bitcoin ecosystem could attract as much as $300 million within the first week of the ETF being approved. That sort of cash flow would certainly help the currency move higher from its current $950 per coin value. But, with all the secrecy surrounding the cryptocurrency is this something you want to be involved in from either owning Bitcoins outright or from the convenience of an ETF? Continue reading "If The Bitcoin ETF Is Approved, Should You Buy It?" →

Gold & Silver: Reversed! What's Next?

Posted on by Aibek Burabayev

Aibek Burabayev - INO.com Contributor - Metals


It’s ironic that people often get puzzled when they get what they wanted or dreamt about. Those who had dreamt of having a baby often panic when the baby is born and think what should we do with this cute toddler?

We are now in the same situation. I called for market a reversal last month and now we got it! Hmm…what’s next? Now that my prediction raised a ton of money I need to carry on using chart analysis only.

Chart 1. Gold Daily: The Santa Claus Rally!

Daily Gold Chart
Chart courtesy of tradingview.com

It was not easy at all for gold to escape from captivity of the blue downtrend. I extended it on the chart above to cover the whole move down as in the previous chart it was half as short as such deep was this move. Continue reading "Gold & Silver: Reversed! What's Next?" →

S&P 500: Prepare For Choppiness

Posted on by Lior Alkalay

Lior Alkalay - INO.com Contributor


After the S&P 500’s rather flat performance over the first three weeks of January, the Index has finally broken higher, pierced through the 2,280 resistance, and seems well on its way to surge above 2,300. So, the question of potential profit taking for the Index at this time may raise some eyebrows. But if we are to take the signals coming from the Federal Reserve over the past few weeks, this is exactly when we should be worried about profit taking and a jump in volatility for the Index.

While the S&P 500 (CME:SP500) was muddling through over the past few weeks, some attributed it to the protectionist stance of the new US president, e.g. the looming threat of a trade war with China, the risk of import levies and, of course, the latest events of this week. President Trump, in a characteristically dramatic fashion, announced the revocation of the Trans-Pacific Partnership Agreement and proclaimed his intention to renegotiate NAFTA, the North American Free Trade Agreement. And how did investors respond? By pushing the S&P 500 up and out of its stagnation and into a new high. Because, while investors are concerned about the risk of a protectionist trade policy, their concerns are somewhat soothed by Trump’s plan to slash the US corporate tax to 15% and boost infrastructure spending.

But what about the S&P 500 are the bulls ignoring? Continue reading "S&P 500: Prepare For Choppiness" →

OPEC's Claim To Eliminate The Oil Glut By June Unsupported By Data

Posted on by Robert Boslego

Robert Boslego - INO.com Contributor - Energies


OPEC reported in its January Monthly Oil Market Report (MOMR) that OECD commercial stocks fell to 2.993 billion barrels, around 271 million barrels above the latest five-year average. Saudi Arabia's energy minister, Khalid Al-Falih, stated last week that production cuts by OPEC and non-OPEC countries may reduce global oil inventories to the five-year average by June thereby rendering a continuation of the cuts unnecessary.

But three closely-watched sources of energy data do not support such a drop in global oil inventories. The Energy Information Administration (EIA), the International Energy Agency (IEA) and OPEC itself published their monthly reports in January, attempting to include impacts of the production cuts. Two of the sources, EIA and OPEC, provide data that show (or imply) stock builds over the first half, and the IEA data show a drawdown but not of the magnitude suggested by Mr. Al-Fahil. Continue reading "OPEC's Claim To Eliminate The Oil Glut By June Unsupported By Data" →

Preview Issue #9: Theranos Layoffs, Amgen Wins and Potential Obamacare Repeal

Posted on by Noah Kiedrowski

INO Health & Biotech Stock Guide

Preview Issue #9 - January 25, 2017

BIOTECH, HEALTH & PHARMA NEWS

2017 is kicking off to be an eventful year in the healthcare space. Regeneron was handed a devastating blow in federal court in a lawsuit filed by Amgen surrounding its cholesterol-lowering drug Praluent. Amgen claimed that Regeneron’s Praluent infringed on Amgen’s patents and competing drug Repatha in a long-standing patent lawsuit. Amgen previously won a trial in which Regeneron was shown to have infringed on two patents covering a class of cholesterol-lowering drugs. The most recent ruling stipulates that Regeneron must stop selling Praluent in the U.S. altogether due to “irreparable harm” to Amgen. It’s extremely rare to see a ruling in which a drug is ordered to be removed from the market as opposed to a financial penalty or royalties. Monetary implications at the moment are minor as Praluent and Repatha have had minimal sales through the first 9 months of 2016 of $75 million and $83 million, respectively. Despite these numbers, if positive data comes to fruition that extends a clinical benefit to more patients in lowering rates of heart attacks, strokes and death then Amgen’s drug could gain broader insurance coverage and ultimately sell $2-$4 billion on an annual basis worldwide. Amgen shares popped 5% on the news while Regeneron shares sank 6% albeit shares were halted once the ruling came down.

WHAT'S NEXT

Continue reading "Preview Issue #9: Theranos Layoffs, Amgen Wins and Potential Obamacare Repeal" →